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MEK INHIBITION RESULTS IN SELECTIVE IMMUNOSUPPRESSION OF
HUMAN T CELLS AND DECREASES CYTOKINE PRODUCTION IN A
MEMORY STAGE-DEPENDENT MANNER
Kim, T.K.1,2, Valencia Gattas, M.1, Benjamin, C.L.1, Levy, R.B1,
Wieder, E.D.1, Komanduri, K.V.1,2 1University of Miami Sylvester Can-
cer Center, Miami, FL; 2M.D. Anderson Cancer Center, Houston, TX
Although allogeneic stem cell transplantation is a treatment of
choice for many hematologic malignancies, a key complication is
graft-versus-host disease (GVHD). Although currently used immu-
nosuppressive medications may successfully inhibit GVHD, none
are selective enough to spare pathogen-specific T cells, leading to
an increased risk of life-threatening infections (e.g., CMV reactiva-
tion). Recent studies suggest that naive and early memory T cells
may be relatively more potent at inducing GVHD, whereas we and
others have shown that most CMV-specific T cells exist as relatively
differentiated cells. Therefore, we reasoned that differences in sig-
naling could be used to selectively inhibit certain maturation stages
of human T cells. Since the MAPK pathway has been demonstrated
to be important for cytokine production in T cells, we measured
phospho-Erk1/2 (p-Erk) in PMA:Ionomycin-treated or SEB-
stimulated CD4+ and CD8 +T cell maturation subsets by flow
cytometry. Naive (CD27 + CD45RA+) and early memory (M1,
CD27 + CD45RA-) T cells expressed three-fold higher p-Erk than
intermediate (M2, CD27-CD45RA-) and late memory (M3,
CD27-CD45RA+) T cells (P\0.05). To test the hypothesis that
the effects of MEK inhibition depend on p-Erk expression, we stim-
ulated T cells from healthy donors using allogeneic dendritic cells
(DC) and assessed alloactivation in the presence or absence of the
MEK inhibitor U0126. U0126-treated CD4+ and CD8 +T cells
were 60-70% less activated than DMSO-treated cells, as assessed
both by CD38 upregulation and CFSE dilution. Nextwedetermined
whether U0126 selectively suppresses cytokine production in a stage-
dependent manner. We stimulated PBMC from healthy subjects
(n5 7) with SEB in the presence of U0126 and measured IL-2,
IFNg and TNFa production in T cell maturation subsets. In
CD4 +T cells, both IL-2 and TNFa production were significantly
more suppressed in naive and early memory cells (Table 1). In CD8+
cells, we similarly saw reductions in IFNg and TNFa production fol-
lowing MEK inhibition (Table 1). Preliminary experiments also sug-
gest that U0126 only minimally suppresses of CMV pp65-specific T
cells from healthy subjects (n5 3), although additional confirmation
is needed. These data demonstrate thatMEK inhibition preferentially
inhibits naive and early memory cells critical for GVHD initiation
while sparing late-memory CMV-specific cells, providing the basis
for more selective clinical strategies for GVHD inhibition.Mean percent reduction in cytokine production in response to
U0126 (n5 7)
Cell Cytokine N M1 M2 M3
CD41 IL-2 79% 56% 50% **
CD41 TNFa 87% 62% 48% **
CD81 IFNg 58% 30% 15% 0%
CD81 TNFa 70% 55% 38% 5%
*all P\0.05 for CD4: N vs. M1, M1 vs. M2, CD8: N vs. M1, M1 vs. M2,
M2 vs. M3.
**M3 cells are not significantly present in CD41 cells.392
STATINS INHIBIT THE ANTIGEN-PRESENTING FUNCTION OF HUMAN B
CELLS
Shimabukuro-Vornhagen, A.1,2, Zoghi, S.2, Liebig, T.2, von Bergwelt-
Baildon, M.1,2 1University Hospital of Cologne, Germany; 2University
Hospital of Cologne, Germany
Statins are lipid-lowering drugs that reduce cholesterol produc-
tion by inhibiting HMG-CoA-reductase the rate-limiting enzymeof the mevalonate pathway. Besides their lipid-lowering effect statins
possess potent immunomodulatory activity. Apart from T cells sev-
eral other immune cells, including B cells, have been shown to be in-
volved in the pathophysiology of graft-versus-host disease (GVHD).
We conducted a expression analysis which showed that the genes of
the mevalonate pathway were upregulated following activation of
human B cells via CD40. Therefore we tested whether statins could
inhibit the activation and antigen-presenting function of B cells as
well as their ability to stimulate the proliferation of allogeneic T
cells. Addition of simvastatin led to a dose-dependent inhibition of
B cell activation and proliferation following stimulation via CD40.
The upregulation of important costimulatory molecules such as
CD80 and CD86 as well as MHC class II was significantly reduced
when simvastatin was added to co-cultures of purified human B cells
with CD40 ligand-expressing fibroblasts. As a consequence the pro-
liferation of allogeneic T cells in response to simvastatin-treated
CD40-activated B cells was significantly decreased compared to un-
treated controls. Addition of atorvastatin had similar effects on
CD40-activated B cells. Surprisingly, the hydrophilic statin pravas-
tatin had no significant effects on B cell activation and antigen-pre-
senting function. Importantly, the doses of simvastatin that were
required for inhibition of the antigen presenting function of B cells
were at least one order of magnitude lower than those required to in-
hibit T cell activation and proliferation induced by anti-CD3/anti-
CD28-coated beads. These results therefore suggest that inhibition
of antigen-presenting cells is an important mechanism by which sta-
tins mediate their immunomodulatory effects. Furthermore, the
observation that pravastatin had no significant effect on antigen-
presenting function has important clinical implications and indicates
that hydrophilic statins like simvastatin should be prefered in future
clinical trials assessing the impact of statins on GVHD.
In summary, our findings demonstrate that statins are promising
immunodulatory agents for the prevention and treatment of
GVHD.This notion is supported by the results of recent clinial trials
which found a reduction in acute and chronic GVHD in patients
which were treated with statins.393
PRIMARY HUMAN ACUTE MYELOID LEUKEMIA STEM CELLS SHOW
REDUCED SENSITIVITY TO NATURAL KILLER CELL-MEDIATED KILLING
Gill, S.1, Majeti, R.2, Bowler, M.1, Negrin, R.S.1 1Stanford University,
Stanford, CA; 2Stanford University, Palo Alto, CA
Introduction:Relapse after initial response to treatment of acute
myeloid leukemia (AML) may be due to the persistence of leu-
kemia stem cells (LSC), which show resistance to chemotherapy.
Currently, the optimal approach to the targeting of LSC is un-
known. In this study, we sought to investigate the potential
graft-versus-leukemia effect of allogeneic natural killer (NK)
cells on AML LSC using immunophenotypic and functional
studies.
Methods: Samples were obtained from the peripheral blood of 11
newly diagnosed patients with AML, under an institutional re-
view board-approved protocol. AML sub-populations were de-
fined based on expression of CD34 and CD38. Initial analysis
included cytofluorometric immunophenotyping of the NK recep-
tor ligand molecules MICA/B, CD112, CD155, HLA-E, MHC
class I, CD48, Fas, DR4 and DR5 in the different AML sub-
populations. Of the 11 samples analysed, four contained an
indentifiable distinct CD34 + CD38- population (defined immu-
nophenotypically as LSC compared to the more mature popula-
tion with the phenotype of CD34 + CD38+), and these were
selected for functional studies. Subpopulations were separated us-
ing fluorescence-activated cell sorting and incubated with effec-
tors (interleukin-2 stimulated purified allogeneic NK cells and
the NK-92 cell line).
Results: Analysis of NK receptor ligands revealed non-significantly
lower expression amongst the LSC population of the activating
NKG2D ligands MICA/B (mean 10.9% +- 2.0 vs 34.7% +- 11.8,
p5 0.16) as well as of the 2B4 ligand CD48 (mean 0.5% +- 0.2 vs
10.3% +- 4.9, p5 0.15). Using a panel of four different effectors,
the putative LSC population and the non-LSC blast population
were found to respond differentially to NK cell-mediated cytototox-
icity, with caspase activation (as a measure of apoptosis) in the blast
Poster Session II S303population ranging up to 80% at an effector to target ratio of 40:1.
The LSC population however was found to be uniformly less sensi-
tive to NK cells than the non-LSC blast population, exhibiting apo-
ptosis that was 45-85% of the more mature population (p5 0.0002
at 10:1 effector-to-target ratio; p5 0.017 at 40:1 effector-to-target
ratio).
Conclusions: Immunophenotypically-defined AML stem cells show
a reduced sensitivity to killing by allogeneic NK cells, a result that
may be related to lower levels of expression of the activating ligands
MICA/B and CD48. These results may have implications for the
utility of natural killer cells in eradicating AML.394
ROLE OF INTERFERON-INDUCED PROCESSES IN LICHENOID SKIN
INFLAMMATION IN CHRONIC GRAFT VERSUS HOST DISEASE
Hakim, F.T.1, Imanguli, M.1, Lafond, S.1, Swaim, W.3, Rehmann, N.1,
Memon, S.1, Cowen, E.2, Pavletic, S.1, Gress, R.E.1 1National Cancer
Institute, NIH, Bethesda, MD; 2National Cancer Institute, NIH,
Bethesda, MD; 3National Institute of Dental and Craniofacial Research,
NIH, Bethesda, MD
Chronic graft versus host disease (CGHD) remains a major non-
relapse source of morbidity and mortality following allogeneic
hematopoietic stem cell transplantation (HSCT), but little is known
of its pathogenesis. As part of an ongoingNCI CGVHDnatural his-
tory protocol (04-C-0281), paired affected and unaffected skin biop-
sies were collected from patients with cutaneous CGVHD. Using
multi-parameter fluorescent immunohistochemistry, we assessed
the dense subepidermal infiltrate of mononuclear cells in skin biop-
sies with lichenoid histological findings in 9 patients. The primary T
cell population in affected skin biopsies consisted of Th1/Tc1 cells
expressing the transcription factor T-Bet. CD8 +T cells predomi-
nated in tissue from patients fewer than 9 months after HSCT, but
were less than CD8-CD3+ cells in biopsies taken from patients
more than one year after HSCT. Both CD68+ myeloid cells in the
dermal infiltrate and epidermal keratinocytes expressed elevated
levels of Interferon (IFN) inducible factors, including MxA and the
chemokineMIG (CXCL9). Concomitantly, most T cells in the infil-
trate expressed the T-Bet induced receptor CXCR3 that bindsMIG.
These findings are consistent with a pathogenic process in which
IFN produced by keratinocytes and infiltrating myeloid elements
could support the recruitment of CXCR3+ effector cells into the
skin. Elevated levels of IFN-inducible factors are also evident sys-
temically. When cells from normal donors were cultured with as
little as 2 pg/ml of Type I IFN,mRNA expression of the IFN-induc-
ible genes BAFF, MxA and IFI44 increased by 2 to 4 logs. Plasma
levels of the IFN-inducible factors MIG and BAFF were elevated
in these patients (MIG median 1813 pg/ml; range 125-7440; BAFF
median 4512; range 1453-14907 pg/ml) compared with normal
donors. These data, and comparable observations we have made in
oral CGVHD (Imanguli, Blood, 2009), support the hypothesis that
IFN-mediated processes contribute to epithelial tissue damage in
CGVHD.395
STAT1 SIGNALING IS CRITICAL FOR ACTIVATION AND DIFFERENTIATION
OF ALLOREACTIVE DONOR LYMPHOCYTES DURING INDUCTION OF
ACUTE GVHD FOLLOWING FULLY MHC-MISMATCHED AND MHC-
MATCHED MHA-MISMATCHED BONE MARROW TRANSPLANTATION
(BMT)
H-H.,Ma1, Lu, C.1, Ziegler, J.1, Lentzsch, S.2, Mapara,M.Y.1 1Univer-
sity of Pittsburgh Cancer Institute, PA; 2University of Pittsburgh Cancer
Institute, PA
We have previously demonstrated that activation of STAT1 and
STAT3 in GVHD target tissues and secondary lymphoid organs be-
long to the earliest events during induction of GVHD. Using
STAT1-gene-deficient (STAT1KO) mice we tested the role of do-
nor STAT1 during GVHD induction in fully MHC-mismatched
(129Sv[H2b] to BALB/c [H2d]) and MHC-matched minor histo-
compatibility antigen (mHA)-mismatched BMT (129Sv[CD45.2,
H2b] to B6 [H2b] or B6.SJL [CD45.1, H2b] following lethal irradi-
ation. Using STAT1KO whole splenocytes we were able to showthat lack of STAT1 significantly inhibited development of GVHD
in both major and mHAmismatched recipients with significantly ex-
tended median survival times (MST), lower GVHD morbidity and
less inflammation in GVHD target tissue samples. Protection
against GVHD in recipients of STAT1KO splenocytes was associ-
ated with significant inhibition of T cell activation as determined
by changes in CD25, CD69 and CD62L expression on donor
CD4+ and CD8 + T cells on days +6 post-BMT. Lack of STAT1
in donor splenocytes resulted in a significantly attenuated and
skewed systemic inflammatory response on day +6 post-BMT as
demonstrated by significantly reduced IFN-g levels (p\0.05), but
significantly increased IL-4 (p5 0.003), IL-5 (p5 0.007) and IL-
17 (p5 0.03) levels. In vitro studies demonstrated that STAT1KO
CD8 +T cells produced much less IFN-g upon combined engage-
ment of TCR and costimulation, but that this decrease in IFN-g se-
cretion could be rescued if cells were simultaneously cultured under
Th1 conditions (i.e. in the presence of IL-12 and anti-IL4 antibody).
In contrast, lack of STAT1 completely inhibited the differentiation
of naive CD4 + T cells to IFN-g-producing cells upon TCR
commitment and this capacity was also severely impaired under
Th1 conditions. These findings were confirmed in vivo in the
MHC-mismatched GVHD setting as we were able to observe a sig-
nificantly reduced number of donor-derived CD4 + IFN-g-produc-
ing cells in recipients of STAT1 KO (p5 0.018) compared to
recipients of WT cells, while there was no difference with regard
to IFN-g expression in CD8 +T cells. Most importantly, we ob-
served a significant expansion of CD4 +CD25 + FOXP3 +Treg cells
in recipients of STAT1KO splenocytes in both major MHC-mis-
matched and MHC-matched mHA-mismatched setting. Currently,
studies are ongoing to assess the role of STAT1 in the generation
and function of Treg cells during GVHD.396
A LOWER FOXP3 + T-REG/CD4 + CELLS RATIO EARLY AFTER HSCT MAY
IDENTIFY PATIENTS AT RISK FOR ALLO-REACTIVE DISEASE
de Pagter, P.J.A.1, Lindemans, C.A.1, Reubsaet, L.L.3, Baarle, D.1,2,
Keukens, L.1, Nanlohy, N.1, Sanders, E.A.M.1, Prakken, B.3,
Kleer, I.M.3, Boelens, J.J.1 1Wilhelmina Children’s Hospital, University
Medical Center Utrecht, Utrecht, Netherlands; 2Wilhelmina Children’s
Hospital, University Medical Center Utrecht, Utrecht, Netherlands;
3Wilhelmina Children’s Hospital, University Medical Center Utrecht,
Utrecht, Netherlands
Regulatory CD4 + FOXP3 +T-cells (FOXP3 +Treg) are sug-
gested to play a role in control of allo-reactive disease after haema-
topoietic stem cell transplantation (HSCT). We analyzed
FOXP3 +Treg in relation to allo-reactive disease after cord blood
(u-CB), matched unrelated donor (MUD) or identical sibling (id-
Sib) HSCT.
In this prospective cohort study, absolute CD4 +T-cell numbers
and the ratio of FOXP3 +Treg of total CD4 + T-cells were analyzed
every other week by direct whole blood Fluorescence-activated cell
sorting analysis. Early allo-reactive disease (\100days) was defined
as acute Graft-versus-Host-Disease and/or idiopathic pulmonary
syndrome after HSCT.
A total of 32 pediatric patients were included. Following myeloa-
blative conditioning, 7 (22%) patients received aMUD, 13 (41%) id-
Sib and 12 (38%) u-CB HSCT. These three patient groups showed
significant differences in the FOXP3 +Treg reconstitution pattern.
The FOXP3 +Treg/CD4+ ratio was higher in the first 6 weeks after
id-Sib-HSCT compared to u-CB or MUD HSCT (p5 0.018). In
u-CB recipients, the FOXP3 +Treg reconstitution was relatively
slow. 12 of the 32 patients developed allo-reactive disease (8 aGvHD
and 4 IPS). Overall, FOXP3 +Treg/CD4+ ratios were lower in
patients prior to the developed allo-reactive disease compared to
patients without allo-reactive disease (p5 0.010).
Development of allo-reactive disease is preceded by a low ratio of
FOXp3 + Treg/CD4 + early after HSCT. The FOXP3 +Treg/CD4
ratio early (6 weeks) after HSCTmight be used to identify patients at
risk for allo-reactive disease and to guide immunosuppressive or im-
muno-therapy. Influencing the ratio of FOXP3 +Treg/CD4+ in vivo
may influence the incidence of allo-reactive disease and may make
HSCT safer.
